Apolipoprotein E2 Reduces the Low Density Lipoprotein Level in Transgenic Mice by Impairing Lipoprotein Lipase-mediated Lipolysis of Triglyceride-rich Lipoproteins
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Apolipoprotein (apo) E2 is often associated with low levels of low density lipoprotein (LDL) cholesterol and high levels of plasma triglycerides in humans. Mice expressing apoE2 also have low LDL levels. To evaluate the possible role of the LDL receptor in the cholesterol-lowering effect of apoE2, we bred transgenic mice expressing low levels of apoE2 with LDL receptor-null mice (hE2(+/0), LDLR-/-). Even in the absence of the LDL receptor, plasma total and LDL cholesterol levels decreased progressively with increasing levels of plasma apoE2. At plasma apoE2 levels >20 mg/dl, LDL cholesterol was approximately 45% lower than in LDLR-/- mice. Thus, the LDL cholesterol-lowering effect of apoE2 is independent of the LDL receptor. In contrast, plasma triglyceride levels increased (mostly in very low density lipoproteins (VLDL) and intermediate density lipoproteins (IDL)) progressively as apoE2 levels increased. At plasma apoE2 levels >20 mg/dl, triglycerides were approximately 150% higher than in LDLR-/- mice. Furthermore, in apoE-null mice (hE2(+/0), mE-/-), apoE2 levels also correlated positively with plasma triglyceride levels, suggesting impaired lipolysis in both hE2(+/0),LDLR-/- and hE2(+/0),mE-/- mice. Incubating VLDL or IDL from the hE2(+/0),LDLR-/- or the hE2(+/0),mE-/- mice with mouse postheparin plasma inhibited lipoprotein lipase-mediated lipolysis of apoE2-containing VLDL and IDL by approximately 80 and approximately 70%, respectively, versus normal VLDL and IDL. This observation was confirmed by studies with triglyceride-rich emulsion particles, apoE2, and purified lipoprotein lipase. Furthermore, apoE2-containing VLDL had much less apoC-II than normal VLDL. Adding apoC-II to the incubation partially corrected the apoE2-impaired lipolysis in apoE2-containing VLDL or IDL and corrected it completely in apoE2-containing emulsion particles. Thus, apoE2 lowers LDL cholesterol by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins (mostly by displacing or masking apoC-II). Furthermore, the effects of apoE2 on both plasma cholesterol and triglyceride levels are dose dependent and act via different mechanisms. The increase in plasma cholesterol caused by apoE2 is due mostly to impaired clearance, whereas the increase in plasma triglycerides is caused mainly by apoE2-impaired lipolysis of triglyceride-rich lipoproteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Self-citationPlump, A. S., Smith, J. D., Hayek, T., Aalto-Setälä, K., Walsh, A., Verstuyft, J. G., Rubin, E. M., & Breslow, J. L. (1992) · Cell · doi:10.1016/0092-8674(92)90362-g · Cited by 2,263
Spontaneous Hypercholesterolemia and Arterial Lesions in Mice Lacking Apolipoprotein E
Zhang, S. H., Reddick, R. L., Piedrahita, J. A., & Maeda, N. (1992) · Science · doi:10.1126/science.1411543 · Cited by 2,237
Apolipoprotein E polymorphism and atherosclerosis.
Davignon, J., Gregg, R. E., & Sing, C. F. (1988) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.8.1.1 · Cited by 1,981
Determinants of atherosclerosis in the young
McGill, H. C., & McMahan, C. A. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00720-6 · Cited by 538
Kowal, R. C., Herz, J., Weisgraber, K. H., Mahley, R. W., Brown, M. S., & Goldstein, J. L. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)87014-4 · Cited by 445
Self-citationHuman Apolipoprotein E4 Domain Interaction
Dong, L.-M., & Weisgraber, K. H. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.32.19053 · Cited by 318
Bellosta, S., Nathan, B. P., Orth, M., Dong, L.-M., Mahley, R. W., & Pitas, R. E. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.45.27063 · Cited by 313
Self-citationUtermann, G., Pruin, N., & Steinmetz, A. (1979) · Clinical Genetics · doi:10.1111/j.1399-0004.1979.tb02028.x · Cited by 209
Rensen, P. C. N., & van Berkel, T. J. C. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.25.14791 · Cited by 144
Cited by
Apolipoprotein E: Far More Than a Lipid Transport Protein
Mahley, R. W., & Rall, S. C. (2000) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.1.1.507 · Cited by 1,836
Self-citationMahley, R. W., & Ji, Z.-S. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33334-4 · Cited by 693
Self-citationMahley, R. W., Huang, Y., & Rall, S. C. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32417-2 · Cited by 447
Self-citationPostprandial lipoprotein metabolism and atherosclerosis.
Karpe, F. (1999) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1999.00548.x · Cited by 360
Apolipoprotein E: from atherosclerosis to Alzheimerʼs disease and beyond
Mahley, R. W., & Huang, Y. (1999) · Current Opinion in Lipidology · doi:10.1097/00041433-199906000-00003 · Cited by 308
Self-citationAPOE2: protective mechanism and therapeutic implications for Alzheimer’s disease
Li, Z., Shue, F., Zhao, N., Shinohara, M., & Bu, G. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00413-4 · Cited by 306
Overexpression and Accumulation of Apolipoprotein E as a Cause of Hypertriglyceridemia
Huang, Y., Liu, X. Q., Rall, S. C., Taylor, J. M., von Eckardstein, A., Assmann, G., & Mahley, R. W. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.41.26388 · Cited by 204
Self-citationAPOE gene variants in primary dyslipidemia
Khalil, Y. A., Rabès, J.-P., Boileau, C., & Varret, M. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.05.007 · Cited by 170
Jendresen, C., Årskog, V., Daws, M. R., & Nilsson, L. N. G. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0835-4 · Cited by 94
Probing the pathways of chylomicron and HDL metabolism using adenovirus-mediated gene transfer
Zannis, V. I., Chroni, A., Kypreos, K. E., Kan, H.-Y., Cesar, T. B., Zanni, E. E., & Kardassis, D. (2004) · Current Opinion in Lipidology · doi:10.1097/00041433-200404000-00008 · Cited by 74
Marais, A. D., Solomon, G. A. E., & Blom, D. J. (2014) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2013.870526 · Cited by 70
Wilsie, L. C., & Orlando, R. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208786200 · Cited by 68
Multiethnic Exome-Wide Association Study of Subclinical Atherosclerosis
Natarajan, P., Bis, J. C., Bielak, L. F., Cox, A. J., Dörr, M., Feitosa, M. F., Franceschini, N., Guo, X., Hwang, S.-J., Isaacs, A., et al. (2016) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.116.001572 · Cited by 66
“ApoE ε2 impairs lipoprotein lipase-mediated metabolism of very low–density lipoprotein to LDL potentially through the displacement of apolipoprotein C-II, an activator of lipoprotein lipase.(43) The consequent diminished hepatic cholesterol may subsequently increase LDL receptors for apolipoprotein B–containing lipopr…”
BackgroundDomains of Apolipoprotein E Contributing to Triglyceride and Cholesterol Homeostasis in Vivo
Kypreos, K. E., van Dijk, K. W., van der Zee, A., Havekes, L. M., & Zannis, V. I. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100418200 · Cited by 62
Hegele, R. A. (2016) · Journal of Lipid Research · doi:10.1194/jlr.c070946 · Cited by 31
“In this pathological state, E2-containing particles accumulate in plasma: increased plasma cholesterol in these patients results from impaired clearance of E2-bearing particles, while increased TG is caused by interference with LPL by E2 (27).”
BackgroundKnouff, C., Malloy, S., Wilder, J., Altenburg, M. K., & Maeda, N. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009423200 · Cited by 28
(2004) · doi:10.1016/j.bbalip.2004.03.004 · Cited by 17
Apolipoprotein E1 Baden (Arg180→Cys)
Hoffmann, M. M., Scharnagl, H., Köster, W., Winkler, K., Wieland, H., & März, W. (2001) · Clinica Chimica Acta · doi:10.1016/s0009-8981(00)00372-7 · Cited by 16
Vezeridis, A. M., Drosatos, K., & Zannis, V. I. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m008409 · Cited by 11
“Other studies have suggested that excess of secreted apoE may partially displace the lipoprotein lipase and/or apoCII and reduce the rate of lipoprotein triglyceride lipolysis [40,41].”
BackgroundCorsetti, J. P., Love, T. M., Sparks, C. E., Bakker, S. J. L., & Dullaart, R. P. F. (2018) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2018.06.009 · Cited by 7
Mejia-Garcia, A., Valderrama-Carmona, P., Zheng, T. M., Wang, Z., Tsao, H. M., Jung, J., Orozco, C. A., Su, C.-Y., & Zhou, S. (2026) · doi:10.64898/2026.09.26.26364080
Metadata
- Authors
- Huang, Y., Liu, X. Q., Rall, S. C., & Mahley, R. W.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1998-07
- Volume
- 273
- Issue
- 28
- Pages
- 17483-17490
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1973309410
- Cited by
- 84
- References
- 13
- FWCI
- 5.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.